Sanofi SA (ADR) (SNY) Files Suit Against Novo Nordisk A/S (ADR) (NVO) Over False Insulin Claims
Novo Nordisk A/S (ADR) (NYSE:NVO) has been sued by Sanofi SA (ADR) (NYSE:SNY) for making false claims.
Sanofi Aventis (SNY)
Market is closed
News
- First
- << Previous
- 101 - 110
- Next >>
EMA Reviews Regeneron Pharmaceuticals Inc (REGN), Sanofi SA (ADR) (SNY) Dupixent MAA
The European Medicines Agency (EMA) has recently accepted to review the Marketing Authorization Application (MAA) of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) for Dupixent...
Sanofi SA (ADR) (SNY) Could Challenge Johnson & Johnson (JNJ) Bid For Actelion Ltd (ALIOF)
Sanofi SA (ADR) (NYSE:SNY) could spark a fierce bidding war for Actelion Ltd (OTCMKTS:ALIOF).
Is Sanofi SA (ADR) (SNY) a Good Stock To Buy?
Is Sanofi SA (ADR) (NYSE:SNY) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research.
Sanofi SA (ADR) (SNY) Facing Manufacturing Headache On Two Blockbusters
Manufacturing problems in France threaten to delay the release of Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN)'s blockbuster drug, dupilumab, according to analysts at Leerink...
US FDA Approves Sanofi SA (ADR) (SNY) Soliqua 100/33, Novo Nordisk A/S (ADR) (NVO) Xultophy 100/3.6
The US Food and Drug Administration (FDA) has recently approved the Soliqua 100/33 (insulin glargine and lixisenatide injection) of Sanofi SA (ADR) (NYSE:SNY) and the Xultophy 100/3.6 (insulin degludec...
Sanofi SA (ADR) (SNY) Can Thank Its Vaccines
Sanofi SA (ADR) (NYSE:SNY) Pasteur seems to be making it big with its vaccines. In the third quarter the French drugmaker’s sales grew by 14% over last year.
Hedge Fund Managers Discuss Shorting Viasat (VSAT), 2U (TWOU), Long Positions in Microsoft (MSFT), Others
Large hedge funds are required to disclose all of their long stakes in U.S.-traded securities once per quarter.
Inside the FDA: Why Sanofi SA (ADR) (SNY) IGlarLixi Was Delayed But Novo Nordisk A/S (ADR) (NVO) IDegLira Wasn’t
Update: Several hours after the initial publication of this report on September 2, Novo Nordisk announced that the FDA has extended the regulatory review for IDeglira, with a decision now expected ...
FDA's Sanofi SA (ADR) (SNY) Delay Highlights Some Red Flags With IGlarLixi
We just learnt that the FDA has pushed back its decision day on Sanofi SA (ADR) (NYSE:SNY)’s insulin combo candidate IGlarLixi.
- First
- << Previous
- 101 - 110
- Next >>
Billionaire Hedge Funds
